Clinical Stage CAR-T for AL Amyloidosis and Immune-Mediated Diseases

September 2024





Disclaimer: Forward Looking Statements & Market Data



This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.'s (the "Company") strategy, future operations, future financial position, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation.

The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation. This presentation also includes data from other approved therapies and in trials, which are generated from separate, independent studies and do not come from head-to-head analysis. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies sourced from publicly available sources. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

Immix Biopharma Highlights



NXC-201: The only CAR-T in AL amyloidosis	 NXC-201 could transform the treatment of Relapsed/Refractory AL amyloidosis (~30,000 prevalence, ~3,000 annual incidence US patients, \$3bn market) NXC-201 CART construct provides barrier to entry NEXICART-1: 92% (12/13) overall response rate with 75% (9/12) complete response rate in patients without prior BCMA bispecifics exposure
Clinical profile ideal for immune-mediated diseases	 Established clinical profile across large 76 patient dataset dosed with NXC-201: well-suited to treat immune-mediated diseases Short duration of cytokine release syndrome Lack of neurotoxicity

Sterically-optimized, proprietary CAR-T construct

- N-GENIUS platform produced NXC-201, our lead, sterically-optimized CAR-T
- 3 key CAR modifications drive unique clinical profile: CD3ζy, CD8 hinge, COBRA binder
- NXC-201 engineered specifically to solve for CAR-T tolerability (cytokine release syndrome, neurotoxicity)

Source:: M. Assayag, et al. Academic BCMA-CART cells (HBI0101), a promising approach for the treatment of LCAmyloidosis. 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT). Late Breaking Oral Presentation. Baltimore, MD. May, 2024. E. Lebel, M.E. Gatt et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relayed and Refractory AL Amyloidosis, 55th AANual Meeting and Exposition, San Diego, CA. October 2023. Quock Ty et al. Epidemiology of AL amyloidosis areal-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadwances.2018016402. PMID: 28748430. Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer 1. 2021;11(8):13440-021. DOIS: 10.1182/bloodadwances.2018016402. PMID: 28748430. Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer 1. 2021;11(8):13470. DOI: 10.1183/bloodadwances.2018016402. PMID: 28748430. Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer 1. 2021;11(8):13470. DOI: 10.1183/bloodadwances.2018016402. PMID: 28748430. Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer 1. 2021;11(8):13470. DOI: 10.1183/bloodadwances.2018016402. PMID: 28748430. Staron A, et al. Marked progress in AL amyloidosis and star 1. Amyloidosis and study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadwances.2018016402. PMID: 28748430. Staron A, et al. Marked progress in AL amyloidosis and star 1. Amyloidosis and star



Upcoming Milestones	Anticipated Timing
Initial NEXICART-2 clinical data presentation in AL Amyloidosis	4Q 2024
Report interim clinical data readout for NEXICART-2 trial in AL Amyloidosis	2Q/3Q 2025
Report NXC-201 interim clinical data in 2 unaddressed immune-mediated diseases	4Q 2025
Report final topline clinical data readout for NEXICART-2 trial in AL Amyloidosis	2Q/3Q 2026

Completed		
NASDAQ IPO 2021		
Formed Cell Therapy R&D ta		
Secured global commercial rights for NXC-201 from Hadassah/Bar-Ilan in 2022		
Reported	ASGCT 2023	
NEXICART-1 AL Amyloidosis interim clinical	ASH 2023	
data at:	ASGCT 2024	
Dosed first US patient in NEX AL Amyloidosis clinical trial	Met mid-2024 guidance	



Lead Program: NXC-201, a next-generation BCMA-targeting CAR-T for AL Amyloidosis and immune-mediated diseases

Indication	Therapy	Pre-clinical	Phase 1	Phase 2	Upcoming Milestones
					4Q 2024: Initial NEXICART-2 clinical data presentation in AL Amyloidosis
Relapsed/Refractory AL Amyloidosis	NXC-201	US FDA and EU EC Orphan Drug De	signation (ODD)		2Q/3Q 2025: Report interim clinical data readout for NEXICART-2 trial in AL Amyloidosis
					2Q/3Q 2026: Report final topline clinical data readout for NEXICART-2 trial in AL Amyloidosis
Undisclosed Immune-Mediated Diseases	NXC-201	IND enabled			4Q 2025: Report NXC-201 interim clinical data in 2 unaddressed immune-mediated diseases

Other Emerging Pipeline

|--|

NXC-201 Referenced in June 2024 New England Journal of Medicine Publication



The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

Dan L. Longo, M.D., Editor

Systemic Light Chain Amyloidosis

Vaishali Sanchorawala, M.D.




Figure 3. Therapeutic Landscape of AL Amyloidosis.

The therapeutic landscape of AL amyloidosis has seen substantial expansion in the past three decades. The majority of treatment regimens are adapted from myeloma therapies, with a focus on targeting the underlying plasma cell clone. Hematologic response has improved significantly with more effective and contemporary treatments, contributing to an overall increase in survival and a reduction in the rate of early death. (CAFT denotes chimeric antigen) receptor T-cell therapy. CR complete hematologic response, CTD cyclophosphamide-thalidomide-dexamethasone, CyBorD cyclophosphamide-bortezomib-dexamethasone, HDM-SCT high-dose melphalan and stem-cell transplantation, Ixazomib-Dex ixazomib-dexamethasone, Len-Dex lenalidomide-dexamethasone, Mel-Dex melphalandexamethasone, and VCPR very good partial hematologic response. tory AL amyloidosis: a multinational retrospective case series. Blood 2024;143: 734-7.

86. Kfir-Erenfeld S, Asherie N, Grisariu S, et al. Feasibility of a novel academic ECMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis. Clin Cancer Res 2022;28:5156-66.


 Nuvolone M, Nevone A, Merlini G. Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis.

TREATMENT OF RELAPSE AND PROGRESSION AFTER INITIAL THERAPY

No consensus has been established on the criteria for commencing second-line therapy in patients with progressive disease after initial therapy.^{73/4} Patients with relapsed disease can be treated by repeating first-line therapy if the response lasted for more than a year, although such patients have a shorter time to relapse without a reduction in overall survival than patients who are treated with a different therapy for relapsed disease.

The potential options available for the treatment of relapsed systemic AL amyloidosis include proteasome inhibitors,75,76 anti-CD-38 monoclonal antibodies,77,78 immunomodulatory agents,79 venetoclax for patients with t(11:14).80 bendamustine,81 high-dose melphalan with autologous SCT, 82,83 bispecific antibodies, 84,85 and even chimeric antigen receptor T-cell therapy.86 Although it is not possible to be prescriptive regarding the sequencing of therapies, the two guiding considerations are the depth and duration of the initial response and the choice of a class of agents not previously used. The limitations imposed by a patient's reduced level of fitness or frailty and end-organ damage must also be considered. Enrollment in clinical trials is encouraged.


World-Class Team



N-GENIUS Platform: Sterically-Optimized CAR-T Construct Drives Differentiated NXC-201 Clinical Profile



ALL BCMA CAR-TS ARE NOT CREATED EQUAL



Immix's proprietary N-GENIUS Platform can overcome the inherent limitations of conventional CAR-T methodologies that lack the sterically-optimized CD3ζγ ("Digital" Signaling), CD8 hinge flexibility, and COBRA binder, which drive NXC-201's greatly reduced neurotoxicity, minimized CRS duration, and enhanced efficacy in heavily pretreated patients

"Single amino acid substitutions at key sites can affect CAR-T function over 200-fold range"

Source: M. Assayag, et al. Academic ECMA-GAT cells (HBIDD1) a promising approach for the treatment of CLA Myndodosis. Tarch A. Londer, et al. Manual Meeting of The American Society of Gene and Cell Therapy (ASCT). Late Breaking Oral Presentationa. Baltimore, M. May, 2024. Fuery, M. Sadebia, et al. doi:10.1016/J. MCG. Total Breaking Oral Presentation and Structure Department of CLA Myndodosis. Tarch A. Londer, et al. Manual Meeting of The American Society of Gene and Cell Therapy (ASCT). Late Breaking Oral Presentationa. Baltimore, M. May, 2024. Fuery, M. Sadebia, et al. doi:10.1016/J. MCG. Total Breaking Oral Presentation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation and structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation on structure Department of CLA Myndodosis. Tarch A. Londer, et al. Predicinal evaluation on structure Department of CLA Myndodosis. Tarch A. Londer, et al.




CARs rely on activation of CAR-T cells through CD3ζ derived immunoreceptor tyrosine-based activation motifs (ITAMs), typically 3 ITAM motifs per CAR

NXC-201 adds a positively charged amino acid (lysine) next to a tyrosine phosphorylation site, therefore:

- ✓ Impeding phosphorylation of ITAM1 (by affecting protein folding dynamics which block the tyrosine site), thus reducing intracellular reactivity
- $\checkmark\,$ Adding an additional site for ubiquitination, allowing the CAR to be marked for degradation more rapidly that a traditional CAR

The combined effect of these modifications is to drive a "digital" signaling of extracellular activity, that is on when antigen is present and off when not

Modification of ITAMs is a common theme in third-generation CAR design, with publications in Nature Medicine and by Memorial Sloan Kettering on the topic



Signal Transduction and Targeted Therapy

doi: 10.1038/s41392-021-00823-w

nature


medicine Memori Cancer

Memorial Sloan Kettering Cancer Center

"We hypothesized that the redundancy of CD28 and CD3ζ signaling in a chimeric antigen receptor (CAR) design incorporating all three CD3ζ immunoreceptor tyrosine-based activation motifs (ITAMs)11,13 may foster counterproductive T cell differentiation and exhaustion. Therefore, we calibrated ITAM activity by mutating tyrosine residues to impede their phosphorylation and downstream signaling"

doi: 10.1038/s41591-018-0290-5





CD32


/4-1BB

2

Proprietary Sterically-Optimized CD3ζ + CD8 Delivers "Digital" Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration



CD8 Hinge



Sterically-optimized (Decreased) CD8 Hinge Flexibility Results in Zero Neurotoxicity, Improved Human Efficacy, and reduction in CRS duration

MM: multiple myeloma

Source: E. Lebel, et, al. Safety And Efficacy of a Locally Produced Novel Anti-BCMA Obtaineric Antigen Receptor T-Cell (CART) (HB0101) for the Treatment of Relapsed and Refractory Multiple Myeloma. 55th ASH Annual Meeting and Exposition, San Diego, CA. December 2023. Ying 2, et al. Nat Med. 2019; Solucter SJ, et al. N Engl J Med. 2019; Astayag, M., et al EBMT 2023; Abecma FDA labe); Harush O, et al. Haematologica. 2022; Friedman KM, et al. Hum Gene Ther. 2018. Mymriah: Preclinical is an average of CDB+ and CDP+ T-cells, source: Milone MC, et Al. Mol Ther. 2009 Aug; 17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278. PMID: 1938/291; PMID: PMC2805264. *1 Day CRS occurred in high dose MM cohort as of EBMT 2023. NXC-201 in multiple myelom data for MASH 2023 95K 001 MR patients within or priorati-BCMM to therapy exposure



Sterically-Optimized COBRA Binder Ensures High Expression And Binding Affinity

COBRA Binder

3


COBRA Binder Leads with	HSL VH (GGGGS) ₅ VL	1.6	■ HSL ■ LSH	
Heavy Chain			Specific Cytotoxicity (%): JeKo1	NXC-201 COBRA Binder: Heavy Chain – Proven Linker –
	doi: 10.3389/fonc.2023.1200914	Day 10 CAR-T Expansion (10^7)	(ROR1+) co-culture	Light Chain Configuration
	Biomarker Research			 ✓ Rapid, Sustained CAR-T Expansion ✓ Improved Cytotoxicity in the presence
Proven Linker of Heavy and Light Chain Employed	"Glycine (Gly) and serine (Ser) residues pro change conformation and maintain good s secondary structures and reduc[ing] likelih the scFv"	tability in aqueous solutions p	prevent[ing] formation of	of antigen
	September 19, 2022 doi: 10.1186/s40364-022-00417-w			



AL Amyloidosis: ~30,000 relapsed/refractory U.S. Patients With No FDA approved drugs



NXC-201 TARGETS AL AMYLOIDOSIS PLASMA CELLS THAT EXPRESS BCMA ON CELL SURFACE




Source: Werlini, G., et al. Nat Rev Dis Primers. Oct 2018, Front. Cardiovasc. Med., Dec 2022, Henato 2022, Jenato 2023, Jin Ar-62, https://doi.org/10.3390/henato.2010.0005. Quock TP, Yan T, Chang E, Guthrie S, Broder MS, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430; PMID: PM75960553: Statistica V PMP area Toxicultural Intraval history study. Blood Cancer. 2021;118(3):10.48; R. Horistics. Unreliance Science V PMID: 29748430; PMID: PM7596053: Statistica V PM74 TOX: Col.2019(1):1031914; R. R. Karlowisci. a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430; PMID: PM7596053: Statistica V PM74 TOX: Col.2019(1):1031914; R. S. Karlowisci. a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430; PMID: PM7596053: Statistica V PM74 TOX: Col.2019(1):1031914; R. S. Karlowisci. a real-world study using US claims data. Blood Adv. 2018 May 22; Alternator 2018; Blood Cancer. 2021; Hill 3319; L. R. Karlowisci. Horiding a Colling May 22; Alternator 2018; Blood Cancer. 2021; Hill 3319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Coll.2019(1):10319; L. R. Karlowisci. Horiding a Colling PM74 TOX: Colling PM74 TOX: Colling PM74 TOX: Colling PM74 TOX: Colling PM

NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population (1/2)

Newly Diagnosed	Relapsed/Refractory		
Newly diagnosed US Incidence ~4,000	Relapsed/Refractory Estimated relapsed/refractory ~3,040 US Prevalence ~29,712 in 2023 (Previously Treated)		
Johnson 4Johnson	Eligible R/R ALA Patients ~32,752		
Combined with cyclophosphamide, bortezomib, and/or dexamethasone) Weekly treatments [FDA approved 2021]	NXC-201 – 75% (9/12) Complete Response rate at ASGCT 2024 One-time treatment Monotherapy Relapsed/Refractory ALA Patients not exposed to BCMA-targeted bispecifics 32,752 Eligible U.S. AL Amyloidosis Patients		
CALLOI Additional	<u>Blue Ocean Opportunity</u> No FDA Approved Drugs in Relapsed / Refractory AL Amyloidosis		

Note: Public information development plans as of 2023. Dara-Cyberlo: Duratumumab, Bortecomib + cyclophophanide + desamethasone. SMO: bortecamib, melphalan, and desamethasone. Source: Dima D, et al. Diagnostic and Treatment Strategies for AL Amyiolosis: provide plans as of 2023. Dara-Cyberlo: Dara-Lunumab, Bortecomib + cyclophophanide + desamethasone. Source: Dima D, et al. Diagnostic and Treatment Strategies for AL Amyiolosis: provide plans as of 2023. Dara-Cyberlo: Dara-Lu223; Jimenez-Zapeda VH, et al. Understanding: real-world treatment and future directions: Surcere approach. Surcere State State

NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population (2/2)



Note: 8% long-term remission estimated based on 20% eligible for SCT x 40% achieving CR (associated with superior long survival)

Source Guock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amploidosis arreival- and/oidosis arreival- advord study using US claim stata. Blood Adv. 2018 May 222(10):1046-1053. doi: 10.1182/biodadvance.2018D16482. PMID: 297484302, PMICI: PMC5956552. Staron A, et al. Amploidosis turnel/avia advorgence incl. 2016 Algo 222(10):1046-1053. doi: 10.1182/biodadvance.2018D16482. PMID: 297484302, PMICI: PMC5956552. Staron A, et al. Amploidosis turnel/avia advorgence incl. 2016 Algo 222(10):1046-1053. doi: 10.1182/biodadvance.2018D16482. PMID: 297484302, PMICI: PMC5956552. Staron A, et al. Amploidosis turnel/avia advorgence incl. 2016 Algo 2016 Algo 222(10):1046-1053. doi: 10.1182/biodadvance.2018D1648. doi: 10.1182/biodadvance.2018D16

NXC-201 May Be a Curative Treatment for AL Amyloidosis


ALL BCMA CAR-TS ARE NOT CREATED EQUAL

AL amyloidosis is caused by dysfunctional plasma cells that can live for years, continuously producing toxic, misfolded amyloid light chain antibody fragments

AL Amyloidosis disease-causing plasma cells:

- Are a minority of total plasma cells
- Are 1 of thousands of antibody-specific plasma cells, each of which produces 1 antibody, specific to 1 target (e.g. common flu, cold, a type of bacteria...)
- Are eliminated by NXC-201 treatment

Then healthy plasma cells regenerate in the months after NXC-201 treatment, potentially preventing disease relapse



NXC-201 Designed for High Activity Against Disease-causing AL Amyloidosis Plasma Cells

2

ALL BCMA CAR-TS ARE NOT CREATED EQUAL



a) <u>Uneven</u> BCMA expression and b) <u>frail patient condition</u> has historically prevented conventional, approved CAR-T use in AL Amyloidosis NXC-201 was designed and tested for human AL Amyloidosis treatment, with preclinical testing revealing that:

the AL Amyloidosis target cells...

...NXC-201 CAR-Ts are activated in presence of

1


BCMA is expressed in 18 AL Amyloidosis patients at a low-medium level...

BCMA Expression (MFI)


10

5

AL



...completely eliminating AL Amyloidosis aberrant plasma cells from patient bone marrow.



NXC-201's uniquely favorable tolerability profile (no neurotoxicity + "Single-day CRS") combined with proven preclinical and clinical efficacy make NXC-201 uniquely suited to treat AL Amyloidosis.


Note: NXC-201 (formerly NBI0101). Infy TNFa for two patients, AL1, AL2. Far right top right quartile selected diseased AL Amyloidosis plasma cell elimination. Far right graph after 33 days co-incubated with NXC-201.

Source: Kfir-Erenfeld S, et al. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022; Raje N, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019.

Primary Efficacy Endpoint for NEXICART-2: Normalization of Diseased Free Light Chains 30 Days after Dosing



NXC-201 RAPIDLY ELIMINATES DISEASED AL AMYLOIDOSIS PLASMA CELLS AND EXITS WITHIN ~30 DAYS




Source: NXC-201 (formerly known as HBI0101). ImmixBio ASGCT Presentation Los Angeles 2023. E. Lebel et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting. 2023.

NXC-201: High Hematologic Responses in R/R AL amyloidosis (\$3bn market) at ASGCT 2024

APPROVAL OF DARZALEX CyBorD IN FRONT-LINE AL AMYLOIDOSIS BASED ON HEMATOLOGIC RESPONSE RATE





NXC-201 – NEXICART-1 Clinical Data

Only CAR-T in AL Amyloidosis

100% Overall Response Rate and 75% Complete Response Rate in Relapsed/Refractory AL amyloidosis for patients without prior BCMA-targeted bispecifics exposure

(median 4 lines of prior therapy prior to NXC-201 – all including Darzalex)

Zero Neurotoxicity of any grade in AL Amyloidosis

Source: Sasyage, et al. Academic BMA-CART cells (HBI010), a promsing approach for the trastment of LCAIT (HBI0101) for the Treatment of Easting of Table American Society of Gene and Cell Therapy (ASCCT). Late Breaking Oral Presentation. Bailtimore, MD. May, 2024. E. Letay, et al. Fassibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Easting Cart Presentation. Easting Presentation. Easting Ca

Ongoing NEXICART-2 Trial to Target Relapsed/ Refractory AL Amyloidosis Patients Most Likely to Benefit



NXC-201 clinical data indicate that R/R Amyloidosis patients with better pre-existing cardiac status and no prior BCMA-targeted bispecifics exposure are more likely to benefit from treatment

Relapsed/Refractory AL Amyloidosis NXC-201 trial	Allows pre-existing severe cardiac patient enrollment?	Allows patients with prior BCMA-targeted therapy exposure?	Allows patients with concomitant Multiple Myeloma?
NEXICART-1: ongoing Israel trial	X Yes	X Yes	X Yes
NEXICART-2: ongoing US trial	✓ No	✓ No	✓ No


40 patient, single-arm, open-label US trial → submit data to FDA

Source: Feasibility of a Novek Academic Anti-BGMA Chimeric Antigen Receptor T-Cell (CART) (HBI0201) for the Treatment of Relaped and Refractory AL Amyloidosis, Seith ASH Annual Meeting and Exposition, San Diego, CA. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis stated and efficary of teclistamab in systemic immunoglobulin light chain amyloidosis stated and effi

NEXICART-1: Durable Responses in NXC-201 AL Amyloidosis Clinical Trial

ONGOING U.S. TRIAL TARGETING R/R AL AMYLOIDOSIS PATIENTS MOST LIKELY TO BENEFIT FROM DURABLE RESPONSES

- Complete hematologic response (CR) of 69% (9/13), and CR 75% (9/12) in patients without prior exposure to BCMA-targeted bispecific, a precedent approval endpoint based on the only commercial treatment for AL amyloidosis
- Ongoing NEXICART-2 US trial targeting patients reflective of durable responders



sCR: strict complete response, CR: complete response

Darzaleer PAD label. Assayage, et al. Academic BMA-CART cells (HBI0101), a promising approach for the treatment of LC AWriolosis. 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT). Late Breaking Oral Presentation. Baltimore, MD. May, 2024. E. Lebel, M.E. Gatt et al. Fessibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relaped and Refractory AL Amojolosis, 15th ASH Annual Meeting and Expositions, San Diego, CA. Dotober 2023.



NEXICART-1: NXC-201 N-GENIUS Platform "Single-Day CRS" Drives AL Amyloidosis Leadership

ALL BCMA CAR-TS ARE NOT CREATED EQUAL

NXC-201's short CRS duration makes it **uniquely suitable to treat ALA patients** (in whom the #1 source of mortality is heart failure)

Cardiovascular stress is the key determinant for ability to treat relapsed/refractory ALA patients

- Long CRS duration causes extended cardiovascular stress
- Other CARTs have 4-8x longer CRS duration

"The biggest challenge ... has been applicability of these therapies in amyloidosis when the patients are particularly frail and have organ dysfunction ... where the key lies in the safety rather the efficacy in a low-volume disease setting is going to be key ... "

 Dr. Susan Bal, MD Assistant Professor, Hematology University of Alabama at Birmingham



SourceAL Assayage, et al. Point-of-care CART manufacture and delivery for the treatment of multiple meydom and AL anyloidosis: the experience of Hadassah Medical Center, European Society for Blood and Marrow Transplantation 49th Annual Meeting. Poster Presentation. April 2023. Nov 2023 KOL discussion https://lifescievents.com/event/immibbio/NXC-201 (formerly HBI0101) American Society of Hematology. Presentation, Abecma FDA approval label, CarvyHtiEDA approval label, Acredits 5.1.


Data in Multiple Myeloma



NEXICART-1: Overcoming Neurotoxicity

ALL BCMA CAR-TS ARE NOT CREATED EQUAL





Source: Carvykii and Abecma FDA labels, Arceld NS-J. Assayage, at J. Academic BCMA-CART cells (HBDID1), a promising approach for the treatment of LC Amyloidosis. 27th Annual Meeting, of The American Society of Gene and Cell Therapy (ASGCT). Late Ereaking O and J. Carvykii and Abecma FDA labels, Arceld NS-J. Assayage, N. et al. European Society for Blood and Marrow Transplantation 49th Meeting. 2023. DHEEting et al. Effects and Effect and Studies of Society 20th Annual Meeting. 2023. DHEEting et al. Effect and Studies of Assayage, N. et al. European Society for Blood and Marrow Transplantation 49th Meeting. 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEting et al. Effect and Studies (Society 20th Annual Meeting, 2023. DHEEti

NEXICART-2 US Relapsed/Refractory AL Amyloidosis Trial (NCT06097832)

NEXICART-2 NXC-201 US TRIAL INITIATED IN MID-2024



	Study design			Status	
Open-label, single-arm Phase 1b/2 study			Lead site Memorial Sloan Kettering and other US sites started mid-2024		
 n=40 patients (majority of whether the second second	ich expected to be enrolled in Phase 2 port	ion)			
	Key criteria				
Inclusion	idosis patients exposed to at least 1 line of t nal antibody	herapy including a CD38		Dere	
Exclusion • Cardiac: N	BCMA directed therapy Aayo stage 3b, NYHA stage III/IV ant Multiple Myeloma		Dose Selection	Dose Expansion	FDA Submission
	Outcome measures				
 Phase 1b: Safety Efficacy: Hematologic responses recommendation amyloidosis 	onse according to to consensus rec		ng informed by NEXICART-1 Amyloidosis were observed		
Relapsed/Refractory AL Amyloidosis NXC-201 trial	Allows pre-existing severe cardiac patient enrollment?	Allows patients with prior B targeted therapy exposur		oatients with Aultiple Myeloma?	Could enrich
NEXICART-1: ongoing Israel trial	XYes	X Yes	X	Yes	ongoing NEXICART-2 US trial for patients more likely to
NEXICART-2: ongoing US trial	✓ No	✓ No	✓	No	benefit from therapy


Note: Hematologic response according to consensus recommendations in AL amyloidosis. (Palladini, et al. 2012. "Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis." Leukemia 26(11): 2317-2325.)



		2021 daratumumab (DARZALEX) FDA Approval	NXC-201 NEXICART-2
	Line of Therapy	Newly Diagnosed	Relapsed/Refractory
	Standard of Care (SoC) at time of trial	3-drug combination: Cyclophosphamide, bortezomib, dexamethasone	✓ None (no FDA approvals)
Patient Characteristics	Randomization vs. Standard of Care?	X Randomization vs. SoC	✓ No SoC to randomize against
	Lines of therapy prior to receiving study drug	× None	 ✓ At least 1 line of therapy including a CD38 monoclonal antibody
Study Design	Statistical Power	Based on the assumption that the percentage of patients with a hematologic complete response would be 15 percentage points higher in the daratumumab group than in the control group; approximately 360 patients were required to provide 85% power to detect this difference (two-sided alpha level of 0.05).	Based on NEXICART-1 complete response (CR) rates, with a sample size of 40 patients , there is a >99% probability that the lower limit of 95% CI for the NXC-201 CR rate is statistically significantly higher compared to historical controls based on the Clopper- Pearson exact method.
	Primary Endpoint	✓ Hematologic complete resp	oonse rate for both studies

Single-arm, open-label FDA approval precedents include: Abecma/BMS (single arm study 100 patients in efficacy results population, FDA approved 2021); Carvykti/J&J (single arm study 97 patients in efficacy results population, FDA approved 2022); Elrexfio/Pfizer (single arm study 97 patients in efficacy results population, FDA approved 2023)

Advantages of CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis



NXC-201 uniquely suited for Relapsed/Refractory AL Amyloidosis




Note: High complete response rates defined as >50%. Low rates of severe infection refers to <30%

Source: Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HB0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, Set 5th ASH Annual Meeting and Exposition, San Diego, CA. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. N. Forgeard, et al. Teclistamab in relapsed or effactory AL amyloidosis, Bandian Tetrospective as series. Blood. February 2024. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. N. Forgeard, et al. Teclistamab in relapsed or effactory AL amyloidosis patient died of COVID-9. Kastritis, et al. Efficacy And Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023 Nov 27,13(1):172. doi: 10.1038/s14408-023-00590-3. PMID: 38012515; PMICID: PMICI0682473. One NXC-201 relapsed/refractory AL amyloidosis and the officacy of teclistamab in systemic immunoglobulin light chain amyloidos: a site officacy And Safety of Delantama Madotin Monotherapy in Patients With Relapsed or Refractory Light-chain Amyloidosis: APase 2 4004 by The European Myeloma Network. Abstract. EHA 2024.

CAR-T NXC-201 Targets Plasma Cells (antibody factories of the body)

ANTIBODY FACTORY PLASMA CELLS PRODUCE ANTIBODIES THAT DRIVE IMMUNE-MEDIATED DISEASES







Source: MediCless, Lee, J. et al. Antigen-specific & Red Bepletion for precision therapy of muscaal penphipus vulgaris. J. Clin mest. 2020. Mackensen, A. et al. Anti-DOB CAR T Cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022. Clin C, et al. Anti-BeCMA CAR T-Cell therapy of muscaal penphipus vulgaris. J. Clin mest. 2020. Mackensen, A. et al. Anti-DOB CAR T Cell therapy for refractory Apple Garagestine according to rest. 2023. Ginc Healt, Mackensen, J. et al. Source and the according to rest. 2023. Ginc Healt, Mackensen, J. et al. Source and the according to rest. 2023. Micro Healt, Mackensen, J. et al. Anti-DOB CAR T-Cell therapy for refractory Apple Garagestine according to rest. 2023. Micro Healt, 202


NXC-201 BCMA CAR-T targeting is uniquely suited to address Immune-Mediated Diseases

NXC-201 BCMA CAR-T TARGETS LONG-LIVED PLASMA CELLS, WHICH ARE OFF-TARGET FOR CD19 THERAPEUTICS










Immix Biopharma unaddressed IMD indication selection criteria

High unmet medical need	
Limited therapies in development	
Biological basis for plasma cell-mediated therapy	

NXC-201 Clinical Development Plan Through FDA BLA Submissions

RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL TO ENROLL 40 PATIENTS PRIOR TO FDA BLA SUBMISSION





Note: 63 Relapsed/Refractory multiple myeloma patients have been dosed with NXC-201 in the ex-US NEXICART-1 clinical trial. Immix Biopharma is not actively pursuing US commercial approval in Relapsed/Refractory multiple myeloma at this time.

FDA approval precedents include: Abecma/BMS (single arm study 100 patients in efficacy results population, FDA approved 2021); Carvykti/J&J (single arm study 97 patients in efficacy results population, FDA approved 2023);

Appendix

September 2024





Principal Investigator for NEXICART-2: Heather Landau, MD





- Director of the Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York.
- Authored more than 100 peer-reviewed publications.
- Dr. Landau received her medical degree from SUNY Upstate Medical University, completed her Internal Medicine residency at University of Colorado and her Hematology & Oncology fellowship at Memorial Sloan Kettering Cancer Center.

NXC-201 CAR-T cells penetrate tissues and repeat kill disease-causing cells in AL Amyloidosis




AL Amyloidosis pathologic light chains emerge from deep in the bone marrow where they are produced by pathologic antibody factory plasma cells

Traditional antibody-based therapies primarily address passively accessible target cells


NXC-201 is the only AL amyloidosis therapy in clinical development that actively penetrates deep into the bone marrow

Diseased AL amyloidosis bone marrow contains densely populated disease-causing antibody factory plasma cells



Immunoperoxidase with hematoxylin counterstain, ×100

These disease-causing plasma cells generate a high density of amyloid deposits that saturate the bone marrow space



Periodic acid–Schiff, ×100

Antibody-based therapeutics have difficulty penetrating deep into organs where disease causing plasma cells reside

Inserm

"Plasma cells (PC) were detected in the [organs] of patients ... up to 6 months after rituximab treatment, and the PC population displayed a long-lived program"

doi:10.1172/JCI65689

Source:N Swan et al. Bone Marrow Core Biopsy Specimens in AL (Primary) Amyloidosis. Hematopathology. Am J Clin Pathol 2003. DOI: 10.1309/PFUGHBX0TY20E08U.. Mahévas M, et al. 8 cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013 Jan;123(1):432-42. doi: 10.1172/JCl65689. Epub 2012 Dec 17. PMID: 23241960; PMCD: PMC353330.

In AL Amyloidosis, NXC-201 Overcomes Limitations of Other Modalities in Performance and Tolerability



Ch	allenges of bispecifics/ T-cell engagers	NXC-201 overcomes these challenges	
•	No clinical trials with clinical data available in relapsed/refractory AL amyloidosis Early data from select centers indicates bispecific responses and tolerability are inferior to CAR-T (NXC-201) in relapsed/refractory AL amyloidosis Retrospective study with 17 R/R multiple myeloma + AL Amyloidosis patients:	 75% CR in relapsed/refractory AL amyloidosis in patients with no prior BCMA-targeted bispecifics exposure 0 deaths from infection in relapsed/refractory AL amyloidosis 0% neurotoxicity (0/13) in relapsed/refractory AL amyloidosis patients One-time dosing with durable responses Ongoing NEXCART-1 relapsed/refractory AL amyloidosis clinical trial with clinical data presented at ASGCT 2024 	Advantages of NXC-201 CAR-T in AL Amyloidosis
•	repear ongoing dosing with need for		

Source: Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBID103) for the Treatment of Relayed and Refractory AL Amyloidosis, Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer Journal. October 2023. R. Chakraborty, et al. Safety and efficacy of teclistamab in systemic immunoglobulin light chain a

healthcare provider to administer



N-GENIUS Platform

Through partnership Hadassah Medical Organization, Jerusalem and Bar-Ilan University, Immix is a pioneer in sterically-optimized CAR-T construct development, driving our next-generation industry-leading CAR-Ts in immune-mediated diseases.

N-GENIUS developed sterically-optimized CAR-Ts allow for a differentiated safety and efficacy profile through modification of key regions of the CAR-T construct, driving a "digital" intracellular signal and overcoming limitations of current clinical stage and commercial CAR-Ts.

Portfolio of US patents, pending applications, and exclusive patent licenses, which cover our core technology platforms and product








N-GENIUS Platform has produced sterically-optimized BCMA CAR-T NXC-201 with COBRA binder and EXPAND technology



ALL BCMA CAR-TS ARE NOT CREATED EQUAL





NXC-201: STERICALLY-OPTIMIZED BCMA CAR-T GENERATED BY THE N-GENIUS PLATFORM



NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) produced by our N-GENIUS platform targeting B-cell maturation antigen (BCMA)

- High Overall Response Rates in AL Amyloidosis and Multiple Myeloma ٠
- First Outpatient CAR-T: Short CRS duration (median 1 days) starting on day 1




Anti-Exhaustion Capability

(Increased Persistence may lead to efficacy over an extended period of time)

NXC-201 was co-cultured overnight then analyzed by flow cytometry for the expression of 4-1BB

CART-ddBCMA






Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421

Proprietary EXPAND Technology and COBRA Binding Domain Are Differentiated Innovations



N-GENIUS TECHNOLOGY PLATFORM: STERICLALLY-OPTIMIZED BCMA CAR-T NXC-201



Note: Graphic representation. COBRA = Codon Optimized Binder for Receptor Antigens – Proprietary Binding Domain



Relapsed/Refractory Light chain (AL) Amyloidosis

		Johnron-Johnron	AstraZeneca	∲prothena [,]
	NXC-201 Monotherapy	Darzalex Combination (with cyclophosphamide, bortezomib, and/or dexamethasone)	CAEL-101	Birtamimab Combined with SOC CyBorD
Dosing frequency	1X	Weekly	Weekly	Weekly
Patient #s: n=	12	9	10 (renal), 24 (cardiac)	14 (cardiac), 15 (renal)
Hematologic Overall Response Rate	100%	22%	-	-
Hematologic Complete Response Rate	75%	0%	-	-
Hematologic CR + VGPR	92%	22%	-	-
Cardiac response – (NT-proBNP median reduction)	61%		39%	35%
Renal response (%)	67%		20%	60%
Median prior lines of therapy	4	1	2	2
% pretreated with CD38-targeted treatment (Darzalex/other)	100%	100%	?	0%

Bitraminab Source from JCO (Bitraminab development passed + restarted), CAEI-101 source: Edwards CV, et al. Phase La/b study of monoclonal antibody CAEI-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020090939. PMID: 34521113; PMCDD: PMC8703360. Daralex source from Blood. Point-of-care CART manufacture and delivery: Poster. Poster Presentation, ESAMT 2023. Poster ASGCT 2023. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Poster: IMS 2023. Poster: ASH 2023. Daralex and Investigator's Choice : Theodoralakou, et al, Blood 2022. Astra Zeneca: Blood 2021 INIC-2019 patients at ASGCT 2024 with no prior exposure to BCMA targeted bispecifics

Differentiated NXC-201 safety profile validated in historical Multiple Myeloma data



				•	
Cytokine release syndrome					
	Cohort 1 (N=6)	Cohort 2 (N=7)	Cohort 3 (N=50)	Overall (n=63)	
Dose	150M	450M	800M		
CRS (n [%])					
Yes	5 (83%)	6 (86%)	48 (96%)	59 (94%)	
No	1 (17%)	1 (14%)	2 (4%)	4 (6%)	
CRS Start Day					
Median	6	0	0		
Min, Max	0, 21	0, 1	0,4		
CRS Duration					
Median	3	2	1		
Min, Max	0,5	1,3	1,7		
CRS Grade (n [%])					
No CRS	1 (17%)	1 (14%)	2 (4%)	4 (6%)	
1	4 (67%)	2 (29%)	17 (34%)	23 (37%)	
2	1 (17%)	4 (57%)	24 (48%)	29 (46%)	
3	0 (0%)	0 (0%)	7 (14%)	7 (11%)	
4	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
Tocilizumab (n [%])					
Yes	2 (33%)	4 (57%)	40 (80%)	46 (73%)	
No	4 (67%)	3 (43%)	10 (20%)	17 (27%)	
Steroids (n [%])					
Yes	0 (0%)	0 (0%)	8 (16%)	8 (13%)	
No	6 (100%)	7 (100%)	42 (84%)	55 (87%)	
Vasopressors (n [%])					
Yes	0 (0%)	0 (0%)	7 (14%)	7 (11%)	
No	6 (100%)	7 (100%)	43 (86%)	56 (89%)	

ICANS neurotoxicity				
	Cohort 1 (N=6)	Cohort 2 (N=7)	Cohort 3 (N=50)	Overall (n=63)
Dose	150M	450M	800M	
ICANS (n [%])				
Yes	0 (0%)	0 (0%)	2 (4%)	2 (3%)
No	6 (100%)	7 (100%)	48 (96%)	61 (97%)
ICANS Grade (n [%])				
1-2	0 (0%)	0 (0%)	2 (4%)	2 (3%)
3-4	0 (0%)	0 (0%)	0 (0%)	0 (0%)

NXC-201 at 150M and 450M CAR+T cell dose (US AL Amyloidosis trial dosing):

- 0% Grade 3+ CRS
- 0% ICANS of any grade

Source: Klin-Eended S, Absterie N, Lebel F, Vainstein V, Assarge M, Dubnikov Sharon T, Grisariu S, Awni B, Blass S, Bleazader-Sharal R, Bessig N, Shehadeh A, Ishtay A, Zellmanovich Y, Zimran E, Pick M, Roainer J, Kenett RS, Cohen Y, Avivi L, Cohen C J, Gatt ME, Stepensky P. Clinical-evaluation and determinants of response to HB00101 (BCMA CART) therapy in relapsed/refractory multiple myeloma: Blood Adv. 2024 Aug 13;8(15):4077-4088. doi: 10.1182/bloodvances.204012967. PMID: 387664428. Asherie N, Klin-Fernelid S, Anity B, Zelman N, Lebel E, Zimran E, Pick M, Roainer J, Kenett RS, Cohen Y, Avivi L, Cohen C J, Gatt ME, Stepensky P. Clinical-evaluation and determinants of response to HB00101 (BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: Results from a phase Lelinical trial. Haematologica. 2023 ul 11;9(1):1207-1289. doi: 10.3324/haematol.2022.281628. PMID: 38200421; PMID: 98200421; PMID: 98700422.

Relapsed/Refractory Multiple Myeloma: Key Inclusion Criteria



	NXC-201 (NEXICART-1 NCT04720313)	Abecma (pivotal NCT03361748)	Carvykti (pivotal NCT03548207)	CART-ddBCMA (pivotal NCT05396885)
Prior lines of therapy	≥3 different prior lines of therapy including proteasome inhibitor, immunomodulatory therapy and ≥1 antibody therapy, refractory/ responsive to the last line of therapy	≥3 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen	≥3 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen, refractory or non-responsive to their most recent line of therapy	≥3 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen
Toxicity recovery	Recovery to ≤Grade 2 or baseline of any non- hematologic toxicities due to prior treatments, excluding alopecia and Grade 3 neuropathy	Recovery to Grade 1 or baseline of any non- hematologic toxicities due to prior treatments	-	Resolution of adverse events (AEs) from any prior systemic anticancer therapy, radiotherapy, or surgery to Grade 1 or baseline
ECOG	0-2	0-1	0-1	0-1
Measurable disease	 Serum M-protein greater or equal to 0.5 g/dL Urine M-protein greater or equal to 200 mg/24 h Serum free light chain (FLC) assay: involved FLC level greater or equal to 5 mg/dL (50 mg/L) provided serum FLC ratio is abnormal 	 Serum M-protein greater or equal to 1.0 g/dL Urine M-protein greater or equal to 200 mg/24 h Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal 	 Serum monoclonal paraprotein (M-protein) level more than or equal to (>=) 1.0 gram per deciliter(g/dL) Urine M-protein level >=200 milligram per 24 hours (mg/24hr) Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio 	 Serum M-protein ≥1.0 g/dL Urine M-protein ≥200 mg/24 hours Involved serum free light chain ≥10 mg/dL with abnormal κ/λ ratio (i.e., >4:1 or <1:2)

Relapsed/Refractory Multiple Myeloma: Key Exclusion Criteria




	NXC-201 (NEXICART-1 NCT04720313)	Abecma (pivotal NCT03361748)	Carvykti (pivotal NCT03548207)	CART-ddBCMA (pivotal NCT05396885)
Prior BCMA therapy	No exclusion	BCMA targeted therapy	Have received any therapy that is targeted to B- cell maturation antigen (BCMA)	Prior B-cell maturation antigen (BCMA) directed therapy
Prior cell therapy	Investigational cellular therapies within 8 weeks prior to the start of lymphodepletion	Investigational cellular therapy for cancer	Have received prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at any target	Prior treatment with any gene therapy or gene- modified cellular immune-therapy

What is autologous chimeric antigen receptor (CAR)-T cell therapy?

NXC-201 IS A NEXT-GENERATION BCMA TARGETED AUTOLOGOUS CAR-T CELL THERAPY





CAR T-cell Therapy

Patient Specific

Personalized treatment using patient's own T cells

Genetic Modification


Genetically engineered CARs (chimeric antigen receptors) on T cell surface

Targeted Therapy

Target cells that express antigens recognized by CARs

N-GENIUS Platform Process





Clinical Stage CAR-T for AL Amyloidosis and Immune-Mediated Diseases

September 2024



